KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Rigel Pharmaceuticals (RIGL) Tax Provisions (2021 - 2025)

Rigel Pharmaceuticals has reported Tax Provisions over the past 3 years, most recently at -$245.4 million for Q4 2025.

  • For Q4 2025, Tax Provisions fell 27949.15% year-over-year to -$245.4 million; the TTM value through Dec 2025 reached -$245.2 million, down 27931.67%, while the annual FY2025 figure was -$245.2 million, 27931.67% down from the prior year.
  • Tax Provisions for Q4 2025 was -$245.4 million at Rigel Pharmaceuticals, down from -$280000.0 in the prior quarter.
  • Over five years, Tax Provisions peaked at $1.8 million in Q1 2021 and troughed at -$245.4 million in Q4 2025.
  • A 3-year average of -$27.1 million and a median of -$95000.0 in 2021 define the central range for Tax Provisions.
  • On a YoY basis, Tax Provisions climbed as much as 27949.15% in 2025 and fell as far as 27949.15% in 2025.
  • Year by year, Tax Provisions stood at -$95000.0 in 2021, then soared by 1027.37% to $881000.0 in 2024, then plummeted by 27949.15% to -$245.4 million in 2025.
  • Business Quant data shows Tax Provisions for RIGL at -$245.4 million in Q4 2025, -$280000.0 in Q3 2025, and $369000.0 in Q2 2025.